A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

What this study is about

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.

Who can join (things the study team will check)

✅ You may be able to join if…

• Male or female aged 18-75 years old with diagnosis of CD for at least 30 days. In South Korea, the age requirement for adult participants is >=19 years of age.
• Confirmed diagnosis of moderately to severely active CD assessed by SES-CD and CDAI.
• Participants must have had an inadequate response to, loss of response to, or intolerance to at least one or more conventional, biologic, or advanced therapy for CD.

🚫 You may not be able to join if…

• Participants with indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, and diverticular disease associated with colitis, and/or ulcerative colitis.
• Have complications of CD that might require surgery during the study.
• Participants with a current ostomy.
• Participants who have failed 3 or more classes of advanced therapies.

Where this trial is running

• United Medical Doctors, Murrieta, California, United States
• UCI Health, Orange, California, United States
• West Central Gastroenterology, LLP, d/b/a/ Gastro Florida, Clearwater, Florida, United States
• Auzmer Research, Lakeland, Florida, United States
• Wellness Clinical Research, Miami Lakes, Florida, United States
• GI PROS, Inc., Naples, Florida, United States
• AdventHealth (Florida Hospital) Medical Group, Orlando, Florida, United States
• USF Health Morsani Center for Advanced Healthcare, Tampa, Florida, United States
• Emory University Hospital, The Emory Clinic, Atlanta, Georgia, United States
• Atlanta Center For Gastroenterology, P.C., Decatur, Georgia, United States
• The University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
• University of Kansas Medical Center, Kansas City, Kansas, United States

+ 178 more sites.

Who to contact

Takeda Contact · +1-877-825-3327 · medinfoUS@takeda.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06233461.